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majority of metabolic effects triggered by
FGF21 occur independently of UCP1.
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A primary target of the pleiotropic metabolic hor-
mone FGF21 is adipose tissue, where it initiates
a gene expression program to enhance energy
expenditure, an effect presumed to be centered on
augmented UCP1 expression and activity. In UCP1
null (UCP1KO) mice, we show that the effect of
FGF21 to increase the metabolic rate is abolished.
However, in contrast to prior expectations, we found
that increased UCP1-dependent thermogenesis is
only partially required to achieve the beneficial
effects of FGF21 treatment. In UCP1KO mice, there
appears to be an underlying reduction in food intake
following FGF21 administration, facilitating weight
loss equal to that observed in wild-type animals.
Furthermore, we show that UCP1-dependent ther-
mogenesis is not required for FGF21 to improve gly-
cemic control or to reduce circulating cholesterol or
free fatty acids. These data indicate that several
important metabolic endpoints of FGF21 are UCP1
independent; however, the contribution of UCP1-
dependent thermogenesis to other discrete aspects
of FGF21 biology requires further study.
INTRODUCTION
The identification of novel therapeutic strategies to safely and
durably treat type 2 diabetes and its associated comorbidities
is of prime importance (Moller, 2012).Oneavenueof investigation
that has gained prominence recently is centered on fibroblast
growth factor 21 (FGF21), a hormone that has been demon-
strated to have significant potential for the treatment ofmetabolic
disease (KharitonenkovandAdams, 2014; ZhangandLi, 2014). In
addition to its role in the response to fasting (Adams and Kharito-
nenkov, 2012; Badman et al., 2009; Inagaki et al., 2007), FGF21 is
also induced in response to cold stress (Chartoumpekis et al.,
2011; Hondares et al., 2011). Under this condition, FGF21 acts
in an autocrine/paracrine manner to engage thermogenic path-
ways inbrownadipose tissue (BAT) andalso to induce thebrown-
ing of white adipose tissue (WAT) (Fisher et al., 2012; Hondareset al., 2011). When secreted by the liver and skeletal muscle,
FGF21 enhances thermogenic activity in BAT in order tomaintain
body temperature in neonates (Hondares et al., 2011). Further-
more, protection against diet-induced obesity (DIO) in FGF21
transgenic mice is proposed to be due in part to increased BAT
mass (Kharitonenkov et al., 2005) and thermogenic activity
(Owen et al., 2014). Administration of FGF21 in models of meta-
bolic disease leads to reduced body weight, improved glycemic
control, and amelioration of dyslipidemia (Zhang and Li, 2014).
Accordingly, there has been an intense focus on gaining a better
understanding of its mechanism of action (Kharitonenkov and
Adams, 2014). As a result, there exists a substantial body of
literature linking the therapeutic benefits of FGF21 to its action
in adipose, where it stimulates thermogenic gene expression
(Adams et al., 2012a, 2012b; Antonellis et al., 2014; Ding et al.,
2012; Holland et al., 2013; Ve´niant et al., 2012).
Following its identification in adult humans, BAT has emerged
as an attractive target in the treatment of metabolic disease due
to its potential to serve as a sink for disposal of excess calories
(Townsend and Tseng, 2014). The primary role of BAT is to main-
tain body temperature during the adaptive response to cold
exposure (Cannon and Nedergaard, 2004). To facilitate this,
BAT utilizes uncoupling protein 1 (UCP1), located within the inner
mitochondrial membrane, to dissipate energy as heat (Cannon
and Nedergaard, 2004). Rodents possess substantial amounts
of UCP1, and its metabolic importance is exemplified by the
obese phenotype of UCP1 null (UCP1KO)mice at thermoneutral-
ity (Feldmann et al., 2009). Conversely, experimental augmenta-
tion of UCP1 activity is reported to improve glucose homeostasis
(Stanford et al., 2013), lower plasma lipids (Bartelt et al., 2011),
and protect against DIO (Whittle et al., 2012). Recent studies
have demonstrated that once it becomes active, human BAT is
also able to make a significant contribution to whole-body en-
ergy expenditures via the oxidation of circulating glucose and
lipids (Chondronikola et al., 2014; Orava et al., 2011). Thus, the
identification of therapeutics that can target BAT may lead to
novel strategies to combat metabolic disease (Tseng et al.,
2010). Importantly, the ability of FGF21 to improve glucose
homeostasis and lower circulating lipids is suggested to be
due in part to its ability to increase UCP1 expression and
enhance caloric expenditure (Adams et al., 2012b; Fisher et al.,
2012). However, the specific contribution of elevated UCP1
expression, increased mitochondrial respiration, and elevatedCell Reports 11, 991–999, May 19, 2015 ª2015 The Authors 991
caloric utilization to discrete aspects of FGF21 biology has not
been delineated.
To evaluate the contribution of UCP1-dependent thermogen-
esis to the pharmacology of FGF21, we treated wild-type (WT)
and UCP1KO mice both acutely and chronically with FGF21.
We show that UCP1-dependent thermogenesis is required for
the full magnitude of the FGF21-induced elevation of energy
expenditure. However, to our surprise, we found that UCP1-
dependent thermogenesis was not required for the anti-obesity
effect of FGF21 or the majority of the other metabolic endpoints
examined.
RESULTS
Consistent with previously published data (Adams et al., 2012b),
we observed a time-dependent effect of FGF21 treatment to
reduce both body weight and fat mass in DIO mice. Body weight
was decreased by approximately 6 g at the end of the 7-day infu-
sion period (Figure 1A). This decrease in body weight was ac-
counted for by a significant decrease in both fat and lean mass
(Figure 1B). There was no significant effect of FGF21 treatment
on daily food intake, which tended to be increased in the
FGF21-treated animals (Figure 1C). There was a significant
improvement in glycemia in mice treated with FGF21. Specif-
ically, blood glucose levels were decreased on day 7 (Figure 1D)
and plasma insulin was reduced on both days 4 and 7 of the
treatment (Figure 1E). In line with previously published data
(Holland et al., 2013; Lin et al., 2013), there was an approximately
30%–40% increase in plasma levels of adiponectin on days 4
and 7 in mice treated with FGF21 (Figure 1F). The effect of
FGF21 to lower circulating triglycerides (Figure 1G), cholesterol
(Figure 1H), and free fatty acids (FFAs; Figure 1I) was apparent
on days 4 and 7 of the treatment.
The anti-obesity effect of FGF21 is proposed to be associated
in part with its ability to increase energy expenditure (Coskun
et al., 2008). However, the kinetics of the onset of this increase
in caloric expenditure following FGF21 administration remains
unknown. To address this issue, we evaluated energy expendi-
ture across the entire 7-day treatment period using home-cage
monitoring of caloric expenditure. In mice treated with FGF21
(expressed relative to body weight [Figure 1J] or per whole ani-
mal [Figure S1A]), there was a time-dependent increase in
energy expenditure, which became statistically significant
48 hr after study onset and remained elevated throughout the
treatment period. Furthermore, there was also a time-dependent
effect of FGF21 to increase lipid oxidation, as evidenced by a
significant and persistent decrease in the respiratory exchange
ratio (RER; Figure 1K). We observed no effect of FGF21 on loco-
motor activity during this study (Figure S1B).
Next, we investigated the effects of FGF21 on thermogenic
gene expression in inguinal WAT (IWAT). On day 4, there was
no effect of FGF21 on metabolic gene expression in IWAT (Fig-
ure S1C). In contrast, following 7 days of treatment, there was
a clear effect on several markers of browning in IWAT, including
genes related to adipocyte cell fate (PR domain containing 16
[PRDM16], peroxisome proliferator-activated receptor gamma
coactivator 1-alpha [PGC1a]), electron transport (cytochrome c
oxidase subunit VIIa [COX7A]), and thermogenesis (UCP1) (Fig-992 Cell Reports 11, 991–999, May 19, 2015 ª2015 The Authorsure S1E). Furthermore, in interscapular BAT (IBAT), FGF21 treat-
ment resulted in a significant increase in key transcriptional
regulators of carbohydrate and fatty acid oxidation (PGC1a
and sirtuin-1 [SIRT1]), markers of thermogenic capacity (bone
morphogenetic protein 8B [BMP8B], cytochrome c oxidase sub-
unit VIIIb [COX8B], type II iodothyronine deiodinase [DIO2], b-3
adrenergic receptor [b3], and UCP1), and substrate transport
(carnitine palmitoyltransferase I [CPT1], fatty acid translocase
[CD36], and glucose transporter type 4 [GLUT4]) after both 4
and 7 days of treatment (Figures S1D and S1F). Thus, the initial
increase in caloric expenditure is primarily associated with
recruitment of IBAT, whereas the full magnitude of FGF21-
induced caloric expenditure only becomes evident on day 7,
when the recruitment of IWAT has also occurred. These data
suggest that in addition to activation of classical BAT, the brown-
ing of WAT is also required for FGF21 to achieve maximal effi-
cacy with regard to energy expenditure.
In order to identify which specific therapeutic outcomes of
FGF21 treatment are dependent upon induction of uncoupled
respiration, we utilized mice with whole-body deletion of UCP1
(Enerba¨ck et al., 1997). Genotype was confirmed via western
blot (Figure 2A). Animals were subjected to 16 weeks of a high-
fat diet, after which the mean body weights were approximately
38 g and 36 g in the WT and UCP1KO groups, respectively (Fig-
ure S2A). Furthermore, there was no difference in basal food
intake between WT and UCP1KO mice (Figure S2B). Next, we
confirmed that expression of FGF receptor 1 (FGFR1) and b-klo-
tho (KLB) in adipose was not different betweenWT and UCP1KO
mice (Figures 2B and 2C). To our surprise, we observed a signif-
icant increase in FGF21 expression in IWAT and IBAT (Figure 2D)
in UCP1KO mice compared with the WT. There was no differ-
ence between genotypes in epididymal WAT (EWAT) (Figure 2D)
or liver (Table S1), suggesting that the potentiation of FGF21
expression in UCP1KO mice is restricted to thermogenically
competent depots. This difference in expression contributed to
a 2.2-fold increase in circulating FGF21 levels in UCP1KO mice
(Figure 2E).
Next, we examined the acute transcriptional response to a sin-
gle subcutaneous (s.c.) injection of FGF21 in EWAT, IWAT, and
IBAT. Consistent with previously published data (Adams et al.,
2012b), induction of the early-response genes c-FOS and
EGR1 was observed in both WT and UCP1KO mice (Figures
2F and 2G). There was no effect of acute FGF21 administration
(45 min) on plasma glucose (Figure 2H), insulin (Figure 2I), adipo-
nectin (Figure 2J), or cholesterol (Figure 2K) levels in either
cohort. Administration of FGF21 in this paradigm significantly
reduced plasma triglycerides levels in WT mice, an effect that
was absent in UCP1KO mice (Figure 2L); however, this discrep-
ancy may be due to the significantly lower basal triglyceride
levels in the UCP1KOmice. In contrast, acute FGF21 administra-
tion lowered plasma FFAs in both the WT and UCP1KO cohorts
(Figure 2M).
Interestingly, chronic administration of FGF21was equally effi-
cacious at reducing bodyweight in obeseWT andUCP1KOmice
(Figures 3A and 3B). Specifically, there was no statistical differ-
ence in the magnitude of weight loss between WT and UCP1KO
mice treated with FGF21 (genotype, p > 0.05). Weight loss was a
result of both reduced fat and lean mass (Figures 3C and 3D).
Figure 1. Chronic Administration of FGF21 Increases Energy Expenditure and Improves Metabolic Homeostasis in DIO Mice
(A–K) Effects of chronic treatment with PBS (vehicle; n = 6) or FGF21 (1 mg/kg/day; n = 6) in DIO mice on cumulative body weight change (A), body composition
(B), daily food intake (C), blood glucose (D), insulin (E), adiponectin (F), triglycerides (G), cholesterol (H), FFAs (I), energy expenditure (J; kcal/kg/hr), and RER (K).
Statistical significance is denoted by *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S1.Furthermore, whereas caloric intake was unchanged in WT mice
(Figure 3E), an approximately 20%decreasewas observed in the
UCP1KO mice (Figure 3F). Chronic FGF21 administration signif-
icantly improved several aspects of glycemic control in both co-
horts of mice. There were decreases in blood glucose (Figure 3G)
and insulin (Figure 3H) accompanied by a significant increase in
adiponectin levels (Figure 3I) irrespective of genotype. With re-
gard to lipids, there was a significant decrease in plasma triglyc-
eride levels in WT mice treated with FGF21; however, similar towhat was observed in the acute treatment paradigm, the triglyc-
eride-lowering effect of FGF21 was absent in UCP1KO animals
(Figure 3J), again likely due to lower basal levels in the UCP1KO
cohort. In contrast, FGF21 was equally effective at lowering
plasma FFA (Figure 3K) and cholesterol (Figure 3L) levels in WT
and UCP1KO mice.
Basal caloric expenditures were similar between vehicle-
treated WT and UCP1KO animals (Figure S2C). Whether ex-
pressed relative to body weight (Figure 4A) or per whole animalCell Reports 11, 991–999, May 19, 2015 ª2015 The Authors 993
Figure 2. FGF21 Increases UCP1 Expression, but Signaling, Gene Expression, and Acute Metabolic Effects of FGF21 Are Maintained in
UCP1KO Mice
(A) UCP1 protein in IBAT from WT and UCP1KO mice.
(B–D) Gene expression of FGFR1 (B), KLB (C), and FGF21 (D) in IBAT, EWAT, and IWAT from WT and UCP1KO mice.
(E) Plasma FGF21 levels in WT and UCP1KO.
(F–M) Acute (45 min) effects of PBS (vehicle) or FGF21 (10 mg/kg) in WT or UCP1KO mice on c-FOS (F) and EGR1 (G) gene expression, blood glucose (H), insulin
(I), adiponectin (J), cholesterol (K) triglycerides (L), and FFAs (M). n = 5 per group. Statistical significance is denoted by *p < 0.05, **p < 0.01, ***p < 0.001.
994 Cell Reports 11, 991–999, May 19, 2015 ª2015 The Authors
Figure 3. The Beneficial Metabolic Effects
of FGF21 Are Maintained in UCP1KO Mice
(A–L) Effects of chronic (7 days) treatment with
PBS (vehicle) or FGF21 (1 mg/kg/day) in WT and
UCP1KO mice on body weight change (A and B),
body composition (C and D), daily food intake
(E and F), blood glucose (G), insulin (H), adipo-
nectin (I), triglycerides (J), FFAs (K), and choles-
terol (L). n = 6 per group. Statistical significance is
denoted by *p < 0.05, **p < 0.01, ***p < 0.001 when
compared with vehicle and #p < 0.05 when
compared with WT. See also Figures S2 and S4.(Figure S3A), chronic FGF21 treatment enhanced energy expen-
diture by approximately 70% inWTmice compared with vehicle-
treated animals. However, FGF21’s ability to increase daily
caloric expenditure was significantly attenuated (15% increase
if expressed relative to body weight [Figure 4B] or completely
abolished if expressed per whole animal [Figure S3A]) in
UCP1KO mice. Furthermore, in WT animals, increased caloric
expenditure was associated with elevated lipid oxidation, as
indicated by a significant decrease in RER (Figure 4C). Mirroring
the attenuation of caloric expenditure, fuel utilization was un-
changed in the UCP1KO mice (Figure 4D). There was no effect
of FGF21 treatment on locomotor activity in WT or UCP1KO
mice (Figures 4E and 4F).
Chronic FGF21 administration potently induced the browning
of IWAT (Figure 5A) and increased thermogenic gene expression
in IBAT (Figure 5C) of WT mice. This change in adipose tissueCell Reports 11, 991–9phenotype in the WT animals was evi-
denced by the significantly increased
expression of key transcriptional regula-
tors (PGC1a), substrate transporters
(CPT1 and CD36), electron transporters
(COX7A and COX8B), and thermogenic
markers (BMP8B, DIO2, and UCP1) in
IWAT (Figure 5A). There was a 27-fold in-
crease in UCP1 protein abundance in
IWAT of WT mice treated with FGF21
(Figure 5A). A compensatory increase in
the expression of several relevant ther-
mogenic genes (BMP8B, DIO2, PGC1a,
and PPARa) was observed in UCP1KO
mice compared with WT (Figures S2D
and S2E). The administration of FGF21
to UCP1KO mice significantly increased
thermogenic gene expression when
normalized to either UCP1KO (Figure 5B)
or WT (Figure S3B) vehicle-treated con-
trol groups. Similar to what was observed
for IWAT, FGF21 significantly increased
the expression of several markers of ther-
mogenic capacity in IBAT ofWTmice and
augmented UCP1 protein abundance
(Figure 5C). However, these FGF21-
induced changes were entirely absent in
IBAT of UCP1KO mice whether theywere normalized to either UCP1KO (Figure 5D) or WT (Fig-
ure S3C) vehicle cohorts. There was a significant increase in
thermogenic gene expression in EWAT of WT and UCP1KO
mice treated with FGF21 (Table S2). Furthermore, in the liver,
FGF21 treatment stimulated the expression of cholesterol 7
alpha-hydroxylase (CYP7A1), leptin receptor (LEPR), and insulin
receptor (INSR), and decreased the expression of stearoyl-CoA
desaturase (SCD1), indicating target engagement in this tissue
irrespective of genotype (Table S1).
Weight loss in UCP1KO mice was associated with a 15% in-
crease in whole-body energy expenditure as well as a 20%
decrease in daily food intake. Therefore, we sought to determine
the contribution of reduced food intake to the observed effects of
FGF21 in this model by pair-feeding vehicle-treated UCP1KO
mice and FGF21-treated UCP1KOmice. As we observed earlier,
chronic FGF21 treatment caused substantial weight loss in both99, May 19, 2015 ª2015 The Authors 995
Figure 4. The FGF21-Mediated Increase in
Caloric Expenditure Is Almost Completely
Abolished in the Absence of UCP1
(A–F) Effects of chronic treatment with PBS
(vehicle) or FGF21 (1 mg/kg/day) in WT and
UCP1KO mice on daily energy expenditure
(A and B), RER (C and D), and daily activity
(E and F). n = 6 per group. Statistical significance is
denoted by *p < 0.05, **p < 0.01, ***p < 0.001. See
also Figures S3 and S4.WT andUCP1KOmice, which again did not differ between geno-
types (Figures S4A and S4B). There was no effect of FGF21
treatment on daily food intake in WT animals (Figure S4C),
whereas a 24% decrease in daily food consumption was
observed in the UCP1KO mice (Figure S4D). Importantly, the
body weight loss in UCP1KOmice pair-fed with the same caloric
intake of the FGF21-treated UCP1KO group was significantly
less than the total weight loss observed in the FGF21-treated
UCP1KO cohort (Figure S4B). It is important to note that in this
pair-feeding paradigm, food was provided prior to the dark
phase, and therefore the animals may not have had food avail-
able in a normal pattern. Nevertheless, these data indicate that
the reduction in absolute caloric intake in UCP1KO mice treated
with FGF21was not sufficient to account for the full magnitude of
weight loss observed.
DISCUSSION
Weight loss following FGF21 administration has been proposed
to be due in part to the induction of caloric expenditure, achieved
via the recruitment of thermogenic pathways in BAT (Adams
et al., 2012b) and the browning of WAT (Fisher et al., 2012).
The primary factor accounting for the thermogenic potential of
WAT and BAT is UCP1 (Cannon and Nedergaard, 2004), a pro-
tein that has recently received significant interest as a potential
mechanism to ameliorate metabolic disease (Harms and Seale,996 Cell Reports 11, 991–999, May 19, 2015 ª2015 The Authors2013). FGF21 has been reported to
enhance UCP1 expression in vitro in pri-
mary murine and human adipocytes, as
well as in vivo in rodent adipose tissue
(Fisher et al., 2012; Lee et al., 2014).
Functionally, elevated UCP1 expression
following FGF21 treatment has been
linked to significantly enhanced oxygen
consumption rates in both cells and ani-
mals (Hondares et al., 2010; Lee et al.,
2014). Utilizing animals with systemic
deletion of UCP1 allowed us to investi-
gate the importance of UCP1 and, by
proxy, energy expenditure with respect
to the phenotypic endpoints of FGF21.
Surprisingly, FGF21 remained effica-
cious in decreasing body weight in mice
with germline deletion of UCP1. Weight
loss in UCP1KO mice appeared to
be associated with both a significantaugmentation of caloric expenditure, independently of UCP1,
and significantly reduced food consumption. Pair-feeding of
UCP1KO mice to FGF21-treated UCP1KO levels indicated that
this reduction in food intake could account for approximately
25% of the decrease in weight. Paradoxically, animal models
such as DIO mice, where FGF21 enhances energy expenditure
dramatically, often show a tendency toward increased food con-
sumption (Coskun et al., 2008). We suggest that this effect may
be compensatory in nature, serving to offset excess caloric
expenditure and maintain mass in a manner similar to the hyper-
phagic response that occurs in rodents as a result of cold stress
(Nikonova et al., 2008). Importantly, in the UCP1KO setting, this
caloric burden is removed, uncovering an underlying depression
of food intake by FGF21.
Previous studies have indirectly attempted to assess the role
of UCP1 in mediating the therapeutic effects of FGF21. Specif-
ically, it was shown that following brown fat lipectomy, FGF21
was still able to potently increase energy expenditure and reduce
body weight (Camporez et al., 2013; Emanuelli et al., 2014). Here
we report that in the absence of UCP1, the ability of FGF21 to
stimulate thermogenic expression in IWAT and IBAT was signif-
icantly attenuated. However, this discrepancy may be a result of
the increased compensatory expression of thermogenic genes
in UCP1KO mice, which would reduce the potential amplitude
of the FGF21-driven increase in these mice compared with
the WT. Our data indicate that although FGF21 may induce
Figure 5. The FGF21-Induced Gene Expression Signature in IWAT and IBAT Is Significantly Attenuated in UCP1KO Mice
(A–D) Effects of chronic treatment with PBS (vehicle) or FGF21 (1 mg/kg/day) on metabolic gene expression and UCP1 protein abundance in IWAT (A and B) and
BAT (C and D) from WT and UCP1KO mice. n = 6 per group. Statistical significance is denoted by *p < 0.05, **p < 0.01, ***p < 0.001. See also Tables S1 and S2.thermogenic gene expression in both IWAT and IBAT in WT
mice, changes in UCP1 expression and/or activity may not be
explicitly required for weight loss. In support of this hypothesis,
FGF21 has also been shown to increase metabolic activity in
the liver and EWAT, as evidenced by elevated oxygen consump-
tion in primary hepatocytes and epididymal adipocytes, and
corroborated by induction of metabolic gene expression (Cam-
porez et al., 2013). In the liver, we also observed a gene expres-
sion profile indicative of enhanced metabolic activity, including
gluconeogenic, fatty acid cycling, and cholesterol-synthesis en-
zymes irrespective of genotype. Furthermore, enhanced caloric
expenditure in UCP1KO mice was also partially underpinned by
the induction of pathways associated with metabolic inefficiency
in EWAT. Therefore, we suggest that in addition to its effect on
UCP1, FGF21may also utilize these pathways to increase caloric
expenditure.
In addition to its effects on weight, FGF21 lowers plasma
glucose, triglyceride, and cholesterol levels (Hale et al., 2012).
Activated BAT has been shown to have a significant capacity
to take up and oxidize circulating lipids in response to cold stress
in rodents and humans (Bartelt et al., 2011; Chondronikola et al.,
2014). Indeed, the effects of FGF21 on circulating lipids are
thought to be associated with enhanced substrate delivery and
consumption by thermogenic pathways in WAT and BAT (Ema-
nuelli et al., 2014). The ability of FGF21 to lower plasma triglycer-ides was absent in UCP1KOmice in the present study; however,
it is important to note that baseline triglyceride levels were
already low in the UCP1KO cohort. In contrast, chronic adminis-
tration of FGF21 lowered plasma FFA and cholesterol levels in
bothWT and UCP1KO cohorts, suggesting that these processes
are independent of adipose tissue thermogenesis, and providing
further support for the hypothesis that these effects of FGF21
may be dependent upon direct action of FGF21 in the liver
(Adams et al., 2012b; Ding et al., 2012; Emanuelli et al., 2014).
Additionally, the glycemic efficacy of FGF21 does not appear
to require UCP1-dependent thermogenesis. Concordant with
the maintenance of glucose lowering in the absence of UCP1,
we observed increased plasma adiponectin levels and lowered
plasma insulin levels irrespective of genotype.
In summary, our data suggest that UCP1-dependent thermo-
genesis is not required for weight loss, decreased cholesterol or
FFA levels, or enhanced glycemic control following chronic
FGF21 administration. In the absence of increased energy
expenditure, the anti-obesity effect of FGF21 was associated
with reduced caloric intake in UCP1KO mice, potentially indi-
cating a central mode of action. Taken as a whole, our data
indicate that although FGF21 potently enhances UCP1 abun-
dance and augments its activity, this effect may not be essential
for many of the therapeutic effects observed with FGF21
treatment.Cell Reports 11, 991–999, May 19, 2015 ª2015 The Authors 997
EXPERIMENTAL PROCEDURES
Animals
All animals were individually housed in a temperature-controlled (26C ±
0.9C) facility with a 12 hr/12 hr light/dark cycle. Animal protocols were
approved by the Eli Lilly and Company IACUC.
Time-Dependent Effects of FGF21
Twenty-four male C57BL/6 mice (10 weeks old) were fed a high-fat/high-
sucrose diet (TD95217; Harlan Teklad) for 12 weeks. The animals were then
weighed and body composition was determined. Osmotic mini-pumps
(ALZET) were then subcutaneously implanted to deliver vehicle (PBS; n = 12)
or hFGF21 (n = 12; 1 mg/kg/day) for 4 or 7 days. Mice assigned to the 7-day
infusion group were housed in metabolic cages (TSE Systems) for the entire
7-day period. Body weight and food intake were recorded daily, and body
composition was assessed again at the end of the experimental period. Prior
to sacrifice, blood glucose levels were determined. Following sacrifice, tissues
were rapidly dissected and flash-frozen in liquid nitrogen.
Acute FGF21 Administration in WT and UCP1KO Mice
The transcriptional effects on adipose tissue of a single s.c. injection of
hFGF21 were assessed in 12-week-old male WT (n = 10) and UCP1KO
(n = 10) mice. Animals received either vehicle (PBS, n = 5) or hFGF21
(10 mg/kg; n = 5). Blood glucose levels were determined 45 min after injection.
Chronic FGF21 Administration in WT and UCP1KO Mice
Twenty-fourmale UCP1KOmice (n = 12) and theirWT (n = 12) siblings (B6.129-
ucp1tmkz/J; The Jackson Laboratory) were fed a high-fat/high-sucrose diet
(TD95217; Harlan Teklad) for 16 weeks. The animals were then weighed and
body composition was determined by quantitative NMR (qNMR). The mice
were then randomly assigned to treatment groups in which osmotic mini-
pumps (ALZET) were subcutaneously implanted to deliver vehicle (PBS;
n = 6) or hFGF21 (1 mg/kg/day; n = 6) for 7 days. Body weight and food intake
were recorded daily. During the final 24 hr of the infusion, themice were placed
in metabolic cages (CLAMS; Columbus Instruments). Seven days after the
start of the experiment, the animals were weighed and body composition
was determined by qNMR.
Pair-Feeding of UCP1KO Mice
Male WT (n = 12) and UCP1KO (n = 18) mice were fed a high-fat/high-sucrose
diet (TD95217; Harlan Teklad) for 16 weeks. WT mice were assigned to one of
two experimental groups (vehicle [n = 6] or FGF21 [n = 6], 1 mg/kg/day).
UCP1KO mice were randomly assigned to one of three experimental groups
(vehicle [n = 6], pair-fed vehicle [n = 6], or FGF21 [n = 6], 1 mg/kg/day). Pair-
feeding of UCP1KO mice was staggered 24 hr behind that of the UCP1KO
mice treated with FGF21. Pair-fed mice were provided food daily prior to the
dark phase. The quantity of food provided was equivalent to the average
food intake of the FGF21-treated UCP1KO mice on the previous day. Animals
were sacrificed in the morning following 7 days of treatment.
Analysis of Metabolites and Circulating Factors
Plasma triglycerides, cholesterol, and FFAs were measured using a Hitachi
912 Clinical Chemistry Analyzer (Roche Diagnostics). Insulin (Crystal Chem),
total adiponectin (BioVendor), and FGF21 (RandD Systems) were measured
by ELISA.
Body Composition Analysis
The body composition of the mice was determined by qNMR analysis (ECHO
MRI, 3-1 Composition Analyzer; Echo Medical Systems).
Western Blotting
Protein was extracted from samples using cell lysis buffer (RIPA buffer;
Thermo Scientific). Membranes were probed with both the primary UCP1 anti-
body (Sigma) and the antibody to the housekeeping protein b-actin (Abcam).
Protein was quantified by densitometry (Quantity One 1-D Analysis software,
version 4.5; Bio-Rad).998 Cell Reports 11, 991–999, May 19, 2015 ª2015 The AuthorsRNA Isolation and Real-Time Quantitative RT-PCR
RNAwas isolated using TRIzol reagent (Invitrogen) and reverse transcribed us-
ing a High-Capacity cDNA Reverse Transcription Kit (PE Applied Biosystems).
Reactions were performed in triplicate on an ABI Prism 7900HT (PE Applied
Biosystems) and normalized to b-actin mRNA (Assays-on-Demand Gene
Expression Products; PE Applied Biosystems). Fold changes were calculated
as 2DDCT.
Statistical Analysis
Data are presented as mean ± SEM. Statistical analysis was performed using
Student’s unpaired t test and one-way ANOVA, followed by Dunnett’s multi-
ple-comparisons test when appropriate. Differences were considered signifi-
cant when p < 0.05.
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